Morgan Stanley predicts that Myriad Genetics’ stock potential growth depends on its hereditary cancer segment.
On Thursday, Morgan Stanley initiated coverage on Myriad Genetics (NASDAQ:) stock, a prominent genetic testing provider, with an Equalweight rating ...
